Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment

被引：7

作者：

Thayer, David ^{[1
]}

Noda, Christopher ^{[1
]}

Charalel, Resmi ^{[1
]}

Mills, Abigail ^{[1
]}

Chang, Randy ^{[2
]}

Tao, Yu ^{[3
]}

Akinwande, Olaguoke ^{[1
,4
]}

机构：

[1] Washington Univ, Mallinckrodt Inst Radiol, Div Intervent Radiol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Div Intervent Radiol, St Louis, MO 63110 USA

[3] Washington Univ, Sch Med, Siteman Biostat, St Louis, MO 63110 USA

[4] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 04期

关键词：

advanced hepatocellular carcinoma; comparative effectiveness; hazard ratio; liver cancer-specific survival; nonoperative treatment; overall survival; palliation; prognostic prediction; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; COHORT; MULTICENTER; SORAFENIB; RESECTION; THERAPY;

D O I：

10.2217/cer-2017-0064

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperative/interventional treatment (NOT). Materials & methods: A total of 12,520 HCC patients from the Surveillance, Epidemiology and End Results database were categorized by treatment with either radioembolization or NOT. Kaplan-Meier and multivariate Cox regression were conducted. Results: The TARE group had both a significantly longer median overall survival than the NOT group (TARE = 9 months; NOT = 2 months; p < 0.0001) and a significantly higher probability of liver cancer-specific survival (hazard ratio = 0.474). Conclusion: TARE appears to provide a significant survival advantage over the NOT population in advanced HCC patients.

引用

页码：343 / 356

页数：14

共 50 条

[1] A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib
de la Torre, Manuel A.
Buades-Mateu, Juan
de la Rosa, Pedro A.
Lue, Alberto
Bustamante, Francisco J.
Serrano, Maria T.
Testillano, Milagros
Lorente, Sara
Arenas, Juan I.
Gil, Cristina
Inarrairaegui, Mercedes
Sangro, Bruno
LIVER INTERNATIONAL, 2016, 36 (08) : 1206 - 1212
[2] Prognostic Nutritional Index Is Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization
Tohme, Samer
Chidi, Alexis P.
Sud, Vikas
Tsung, Allan
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 28 (03) : 470 - 472
[3] Pattern of progression determines post-progression survival in patients with hepatocellular carcinoma treated with Radioembolization
Jordan, C.
de la Torre, M.
Gardini, A. C.
Bilbao, J. I.
Rodriguez-Fraile, M.
Rodriguez, L. S.
D'avola, D.
Inarrairaegui, M.
Herrero, J. I.
Quiroga, J.
Sangro, B.
JOURNAL OF HEPATOLOGY, 2018, 68 : S13 - S13
[4] Radioembolization for the treatment of hepatocellular carcinoma
Kim, Hyo-Cheol
CLINICAL AND MOLECULAR HEPATOLOGY, 2017, 23 (02) : 109 - 114
[5] Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma
Golfieri, Rita
Ignacio Bilbao, Jose
Carpanese, Livio
Cianni, Roberto
Gasparini, Daniele
Ezziddin, Samer
Paprottka, Philipp Marius
Fiore, Francesco
Cappelli, Alberta
Rodriguez, Macarena
Ettorre, Giuseppe Maria
Saltarelli, Adelchi
Geatti, Onelio
Ahmadzadehfar, Hojjat
Haug, Alexander R.
Izzo, Francesco
Giampalma, Emanuela
Sangro, Bruno
Pizzi, Giuseppe
Notarianni, Ermanno
Vit, Alessandro
Wilhelm, Kai
Jakobs, Tobias F.
Lastoria, Secondo
JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 753 - 761
[6] PERFORMANCE OF THE HAP SCORE AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY RADIOEMBOLIZATION
Buades Mateu, J.
Martinez-Urbistondo, D.
De la Torre Alaez, M.
Inarrairaegui, M.
Bilbao, J. I.
Sangro, B.
JOURNAL OF HEPATOLOGY, 2016, 64 : S695 - S695
[7] Long term outcome of patients with hepatocellular carcinoma treated with transarterial radioembolization
Prussia, C.
De Giorgio, M.
Vigano, M.
Muglia, R.
Marra, P.
Gerali, A.
Erba, P.
Poli, Gl.
Fagiuoli, S.
DIGESTIVE AND LIVER DISEASE, 2023, 55 : S219 - S219
[8] Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma
Laura E. Moreno-Luna
Ju Dong Yang
William Sanchez
Ricardo Paz-Fumagalli
Denise M. Harnois
Teresa A. Mettler
Denise N. Gansen
Piet C. de Groen
Konstantinos N. Lazaridis
K. V. Narayanan Menon
Nicholas F. LaRusso
Steven R. Alberts
Gregory J. Gores
Chad J. Fleming
Seth W. Slettedahl
William S. Harmsen
Terry M. Therneau
Gregory A. Wiseman
James C. Andrews
Lewis R. Roberts
CardioVascular and Interventional Radiology, 2013, 36 : 714 - 723
[9] Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma
Moreno-Luna, Laura E.
Yang, Ju Dong
Sanchez, William
Paz-Fumagalli, Ricardo
Harnois, Denise M.
Mettler, Teresa A.
Gansen, Denise N.
de Groen, Piet C.
Lazaridis, Konstantinos N.
Menon, K. V. Narayanan
LaRusso, Nicholas F.
Alberts, Steven R.
Gores, Gregory J.
Fleming, Chad J.
Slettedahl, Seth W.
Harmsen, William S.
Therneau, Terry M.
Wiseman, Gregory A.
Andrews, James C.
Roberts, Lewis R.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 36 (03) : 714 - 723
[10] Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria
Ghosn, M.
Derbel, H.
Kharrat, R.
Oubaya, N.
Mule, S.
Chalaye, J.
Regnault, H.
Amaddeo, G.
Itti, E.
Luciani, A.
Kobeiter, H.
Tacher, V.
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2021, 102 (01) : 35 - 44

← 1 2 3 4 5 →